JP Morgan Reinstates Underweight on Nektar Therapeutics
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye has reinstated coverage on Nektar Therapeutics (NASDAQ:NKTR) with an Underweight rating.
November 20, 2023 | 1:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan analyst Jessica Fye has reinstated Nektar Therapeutics with an Underweight rating, indicating a bearish outlook on the stock.
Analyst ratings, especially from prominent financial institutions like JP Morgan, can significantly influence investor sentiment and stock prices. An Underweight rating suggests that the analyst believes the stock will underperform the industry or the overall market, which could lead to a decrease in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100